WO2002085332A1 - A pharmaceutical tablet system that floats on gastric fluid for multipulse release of active substance and respective processes of producing same and a cup-shaped envelope of same - Google Patents
A pharmaceutical tablet system that floats on gastric fluid for multipulse release of active substance and respective processes of producing same and a cup-shaped envelope of same Download PDFInfo
- Publication number
- WO2002085332A1 WO2002085332A1 PCT/IB2002/000959 IB0200959W WO02085332A1 WO 2002085332 A1 WO2002085332 A1 WO 2002085332A1 IB 0200959 W IB0200959 W IB 0200959W WO 02085332 A1 WO02085332 A1 WO 02085332A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- release
- cup
- tablet system
- core
- shaped envelope
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title claims abstract description 55
- 230000002496 gastric effect Effects 0.000 title claims abstract description 45
- 239000012530 fluid Substances 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 title claims description 29
- 230000008569 process Effects 0.000 title claims description 18
- 239000000463 material Substances 0.000 claims abstract description 45
- 239000000203 mixture Substances 0.000 claims abstract description 35
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 22
- 230000006835 compression Effects 0.000 claims abstract description 19
- 238000007906 compression Methods 0.000 claims abstract description 19
- 239000000945 filler Substances 0.000 claims abstract description 19
- 239000000126 substance Substances 0.000 claims abstract description 18
- 230000002035 prolonged effect Effects 0.000 claims abstract description 14
- 238000007667 floating Methods 0.000 claims abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 5
- 239000008187 granular material Substances 0.000 claims description 27
- 239000011248 coating agent Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 3
- 239000010410 layer Substances 0.000 description 55
- 210000002784 stomach Anatomy 0.000 description 29
- 239000003795 chemical substances by application Substances 0.000 description 20
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 15
- 239000008101 lactose Substances 0.000 description 15
- 239000008119 colloidal silica Substances 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 238000004090 dissolution Methods 0.000 description 10
- 230000037406 food intake Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000004359 castor oil Substances 0.000 description 9
- 235000019438 castor oil Nutrition 0.000 description 9
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 9
- 239000003562 lightweight material Substances 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 8
- 229960004166 diltiazem Drugs 0.000 description 8
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 6
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 6
- 235000019700 dicalcium phosphate Nutrition 0.000 description 6
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 229940049654 glyceryl behenate Drugs 0.000 description 6
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 6
- 229910002012 Aerosil® Inorganic materials 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 229920003072 Plasdone™ povidone Polymers 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 210000004400 mucous membrane Anatomy 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 239000001828 Gelatine Substances 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 239000012738 dissolution medium Substances 0.000 description 3
- 239000008240 homogeneous mixture Substances 0.000 description 3
- 239000000416 hydrocolloid Substances 0.000 description 3
- 239000010514 hydrogenated cottonseed oil Substances 0.000 description 3
- 210000001187 pylorus Anatomy 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241001440269 Cutina Species 0.000 description 2
- 241000138806 Impages Species 0.000 description 2
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000005245 sintering Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/473,055 US7838028B2 (en) | 2001-03-31 | 2002-03-18 | Pharmaceutical tablet system that floats on gastric fluid for multipulse release of active substance, and respective processes of producing same and a cup-shaped envelope of same |
JP2002582906A JP4276437B2 (en) | 2001-03-31 | 2002-03-18 | Pharmaceutical tablet system that floats on gastric juice for multi-pulse release of active substance, as well as its manufacturing method and its cup-shaped outer shell manufacturing method |
CA2441123A CA2441123C (en) | 2001-03-31 | 2002-03-18 | A pharmaceutical tablet system that floats on gastric fluid for multipulse release of active substance, and respective processes of producing same and a cup-shaped envelope of same |
EP02716969A EP1372612A1 (en) | 2001-03-31 | 2002-03-18 | A pharmaceutical tablet system that floats on gastric fluid for multipulse release of active substance, and respective processes of producing same and a cup-shaped envelope of same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01108252A EP1245227A1 (en) | 2001-03-31 | 2001-03-31 | A pharmaceutical tablet system that floats in the stomach for programmed release of active substance and process of producing buoyant material contained in same |
EP01108252.6 | 2001-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002085332A1 true WO2002085332A1 (en) | 2002-10-31 |
Family
ID=8177016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2002/000959 WO2002085332A1 (en) | 2001-03-31 | 2002-03-18 | A pharmaceutical tablet system that floats on gastric fluid for multipulse release of active substance and respective processes of producing same and a cup-shaped envelope of same |
Country Status (6)
Country | Link |
---|---|
US (1) | US7838028B2 (en) |
EP (2) | EP1245227A1 (en) |
JP (1) | JP4276437B2 (en) |
CN (1) | CN100589793C (en) |
CA (1) | CA2441123C (en) |
WO (1) | WO2002085332A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006524230A (en) * | 2003-04-24 | 2006-10-26 | ヤゴテック アーゲー | Tablet with colored core |
DE102007026037A1 (en) | 2007-06-04 | 2008-12-11 | Lts Lohmann Therapie-Systeme Ag | Gastroretentive system with alginate body |
US8372225B2 (en) | 2005-11-18 | 2013-02-12 | Glaxo Group Limited | Machine and method for pharmaceutical and pharmaceutical-like product assembly |
US8858960B2 (en) | 2004-11-19 | 2014-10-14 | GlaxoSmithKline, LLC | Method of producing a pharmaceutical product |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070178155A1 (en) * | 2006-01-31 | 2007-08-02 | Jiang David Yihai | Preparation for gastric buoyant sustained drug release dosage form |
ES2718211T3 (en) | 2013-05-24 | 2019-06-28 | Rhodes Tech | Opioid ketal compounds and uses thereof |
DE102014003744A1 (en) | 2014-03-10 | 2015-09-10 | Laboratorium für Lebensmittelwissenschaft (FPE) - Eidgenössische Technische Hochschule Zürich (ETH) | Product for oral administration to humans or animals with microstructured encapsulated ingredients, and apparatus for making such a product, and method of making the same |
CN113476421B (en) * | 2017-12-29 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | Controlled release composition of febuxostat and preparation method thereof |
JP7284764B2 (en) | 2018-02-23 | 2023-05-31 | ロデス テクノロジーズ | Novel opioid compounds and uses thereof |
JP2023516370A (en) * | 2020-03-02 | 2023-04-19 | クラフト ヘルス プライベート リミテッド | Oral dosage form for sustained drug release |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
US4814179A (en) * | 1985-04-12 | 1989-03-21 | St. John's University | Floating sustained release therapeutic compositions |
JPH0624959A (en) * | 1991-10-04 | 1994-02-01 | Bayer Yakuhin Kk | Medice release solid pharmaceutical preparation of gastric suspending type sustained |
EP0669129A2 (en) * | 1994-02-28 | 1995-08-30 | Bayer Ag | Expandable release controlled medicaments |
EP0788790A2 (en) * | 1996-02-06 | 1997-08-13 | Jagotec Ag | Pharmaceutical tablet suitable to deliver the active substance in subsequent and predeterminable times |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5512411B2 (en) * | 1974-03-12 | 1980-04-02 | ||
CH630257A5 (en) * | 1975-03-17 | 1982-06-15 | Hoffmann La Roche | Sustained release formulation |
US4126672A (en) * | 1976-02-04 | 1978-11-21 | Hoffmann-La Roche Inc. | Sustained release pharmaceutical capsules |
US4167558A (en) * | 1976-02-13 | 1979-09-11 | Hoffmann-La Roche Inc. | Novel sustained release tablet formulations |
GB1576376A (en) * | 1977-03-30 | 1980-10-08 | Benzon As Alfred | Multiple-unit drug dose |
US4101650A (en) * | 1977-04-06 | 1978-07-18 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Pepstatin floating minicapsules |
US4434153A (en) * | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
JPS6143108A (en) * | 1984-08-03 | 1986-03-01 | Nippon Shinyaku Co Ltd | Medicinal drug and its preparation |
EP0202159B1 (en) | 1985-05-10 | 1991-07-03 | Merck & Co. Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
US4735804A (en) * | 1985-05-10 | 1988-04-05 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
US4758436A (en) * | 1985-05-29 | 1988-07-19 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
US4767627A (en) * | 1985-05-29 | 1988-08-30 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
JPS62195323A (en) * | 1986-02-24 | 1987-08-28 | Eisai Co Ltd | Gastric resident particle |
US5374430A (en) * | 1986-09-18 | 1994-12-20 | London School Of Pharmacy | Pharmaceutical formulation |
US4814178A (en) * | 1987-07-01 | 1989-03-21 | Sanford Bolton | Floating sustained release therapeutic compositions |
JPS6416715A (en) | 1987-07-10 | 1989-01-20 | Kyoto Pharma Ind | Intragastric floating pharmaceutical |
IL87710A (en) * | 1987-09-18 | 1992-06-21 | Ciba Geigy Ag | Covered floating retard form for controlled release in gastric juice |
DE3803482A1 (en) * | 1988-02-05 | 1989-08-17 | Lohmann Therapie Syst Lts | FLOATING ORAL THERAPEUTIC SYSTEM |
GB8809421D0 (en) * | 1988-04-21 | 1988-05-25 | Fordonal Sa | Antacid compositions with prolonged gastric residence time |
US5002772A (en) * | 1988-05-31 | 1991-03-26 | Pfizer Inc. | Gastric retention system for controlled drug release |
US5169639A (en) * | 1988-09-19 | 1992-12-08 | Edward Mendell Co., Inc. | Controlled release verapamil tablets |
JPH0795889B2 (en) | 1989-06-07 | 1995-10-18 | 松山株式会社 | Mining machine |
DK469989D0 (en) * | 1989-09-22 | 1989-09-22 | Bukh Meditec | PHARMACEUTICAL PREPARATION |
DE4036757A1 (en) * | 1990-11-17 | 1992-05-21 | Bayer Ag | ANTAZIDA PREPARATION WITH EXTENDED STOMACH TEMPERING |
US5232704A (en) * | 1990-12-19 | 1993-08-03 | G. D. Searle & Co. | Sustained release, bilayer buoyant dosage form |
US5198229A (en) * | 1991-06-05 | 1993-03-30 | Alza Corporation | Self-retaining gastrointestinal delivery device |
IT1249980B (en) | 1991-08-07 | 1995-03-30 | Comau Spa | DEVICE FOR THE WELDING OF STRUCTURES, SUCH AS BODIES OF MOTOR VEHICLES OR PARTS OF THEM, MADE UP OF ELEMENTS OF PRINTED SHEET METAL ASSEMBLED PRELIMINARILY AMONG THEM IN A LABULAR WAY. |
US5571533A (en) * | 1992-02-07 | 1996-11-05 | Recordati, S.A., Chemical And Pharmaceutical Company | Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide |
GB9211148D0 (en) | 1992-05-26 | 1992-07-08 | Smithkline Beecham Plc | Novel treatment |
US5360793A (en) * | 1993-05-24 | 1994-11-01 | Sterling Winthrop Inc. | Rafting antacid formulation |
IT1264517B1 (en) | 1993-05-31 | 1996-09-24 | Ekita Investments Nv | PHARMACEUTICAL TABLET SUITABLE FOR THE RELEASE IN SUBSEQUENT TIMES OF THE ACTIVE PRINCIPLES CARRIED THEREIN |
DE69613966T2 (en) | 1995-03-17 | 2002-04-04 | Boots Co Ltd | PHARMACEUTICAL COMPOSITIONS WITH PECTIN |
AU3290397A (en) | 1996-06-10 | 1998-01-07 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
JP3825811B2 (en) | 1997-01-14 | 2006-09-27 | エルティエス ローマン テラピー−ズュステーメ アーゲー | Inflatable gastric retention treatment system using controlled release of active substance in the gastrointestinal system |
KR20000076329A (en) | 1997-03-25 | 2000-12-26 | 다케다 야쿠힌 고교 가부시키가이샤 | Gastrointestinal mucosa-adherent pharmaceutical composition |
FR2762213B1 (en) | 1997-04-18 | 1999-05-14 | Synthelabo | PHARMACEUTICAL COMPOSITION WITH GASTRIC RETENTION |
GB9710699D0 (en) | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
US6342249B1 (en) * | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
EP1074249A1 (en) | 1999-07-27 | 2001-02-07 | Jagotec Ag | A pharmaceutical tablet system for releasing at least one active substance during a release period subsequent to a no-release period |
-
2001
- 2001-03-31 EP EP01108252A patent/EP1245227A1/en not_active Withdrawn
-
2002
- 2002-03-18 WO PCT/IB2002/000959 patent/WO2002085332A1/en not_active Application Discontinuation
- 2002-03-18 EP EP02716969A patent/EP1372612A1/en not_active Withdrawn
- 2002-03-18 CA CA2441123A patent/CA2441123C/en not_active Expired - Fee Related
- 2002-03-18 JP JP2002582906A patent/JP4276437B2/en not_active Expired - Fee Related
- 2002-03-18 US US10/473,055 patent/US7838028B2/en not_active Expired - Fee Related
- 2002-03-18 CN CN02807431A patent/CN100589793C/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
US4814179A (en) * | 1985-04-12 | 1989-03-21 | St. John's University | Floating sustained release therapeutic compositions |
JPH0624959A (en) * | 1991-10-04 | 1994-02-01 | Bayer Yakuhin Kk | Medice release solid pharmaceutical preparation of gastric suspending type sustained |
EP0669129A2 (en) * | 1994-02-28 | 1995-08-30 | Bayer Ag | Expandable release controlled medicaments |
EP0788790A2 (en) * | 1996-02-06 | 1997-08-13 | Jagotec Ag | Pharmaceutical tablet suitable to deliver the active substance in subsequent and predeterminable times |
Non-Patent Citations (1)
Title |
---|
PATENT ABSTRACTS OF JAPAN vol. 018, no. 236 (C - 1196) 6 May 1994 (1994-05-06) * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006524230A (en) * | 2003-04-24 | 2006-10-26 | ヤゴテック アーゲー | Tablet with colored core |
JP4908200B2 (en) * | 2003-04-24 | 2012-04-04 | ヤゴテック アーゲー | Tablet with colored core |
US8858960B2 (en) | 2004-11-19 | 2014-10-14 | GlaxoSmithKline, LLC | Method of producing a pharmaceutical product |
US8372225B2 (en) | 2005-11-18 | 2013-02-12 | Glaxo Group Limited | Machine and method for pharmaceutical and pharmaceutical-like product assembly |
US9187192B2 (en) | 2005-11-18 | 2015-11-17 | Glaxo Group Limited | Machine and method for pharmaceutical and pharmaceutical-like product assembly |
DE102007026037A1 (en) | 2007-06-04 | 2008-12-11 | Lts Lohmann Therapie-Systeme Ag | Gastroretentive system with alginate body |
EP2497465A2 (en) | 2007-06-04 | 2012-09-12 | LTS LOHMANN Therapie-Systeme AG | Gastroretentive system with alginate body |
Also Published As
Publication number | Publication date |
---|---|
EP1372612A1 (en) | 2004-01-02 |
US20040166161A1 (en) | 2004-08-26 |
CA2441123A1 (en) | 2002-10-31 |
JP4276437B2 (en) | 2009-06-10 |
EP1245227A1 (en) | 2002-10-02 |
CN1499961A (en) | 2004-05-26 |
CN100589793C (en) | 2010-02-17 |
US7838028B2 (en) | 2010-11-23 |
JP2004532222A (en) | 2004-10-21 |
CA2441123C (en) | 2011-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005235239B2 (en) | Gastric retention system | |
US5582837A (en) | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms | |
EP0467975B1 (en) | Sustained-release oral drug dosage form | |
US4424235A (en) | Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor | |
EP1406568B1 (en) | Sequential drug delivery systems | |
CA1073358A (en) | Sustained release formulations | |
AU3811493A (en) | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms | |
US20170042839A1 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
JP2010120956A (en) | Easy to swallow oral medicament composition | |
JP2001524956A (en) | Fast dissolving, robust dosage form | |
WO1997047285A1 (en) | Gastric-retentive oral controlled drug delivery system with enhanced retention properties | |
JPH09316005A (en) | Pharmaceutical compressed tablet capable of highly increasing volume by contact with body fluid | |
PL129290B1 (en) | Method of obtaining new forms of dipyridamole exhibiting prolonged action | |
US20150250746A1 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
US7838028B2 (en) | Pharmaceutical tablet system that floats on gastric fluid for multipulse release of active substance, and respective processes of producing same and a cup-shaped envelope of same | |
JPH09509412A (en) | 2-layer amoxicillin tablets | |
EP1014952A1 (en) | Multiple unit effervescent dosage form | |
GB2105590A (en) | Flotable controlled release preparations | |
Advankar et al. | Specialized tablets: Ancient history to modern developments | |
AU6848700A (en) | Floating pharmaceutical composition comprising an active phase and a non-active phase | |
JP2005524670A (en) | Controlled release dosage form | |
JP2003514846A (en) | Multi-layer formulation for controlled pulsatile release of active substance | |
AU2002247893A1 (en) | A pharmaceutical tablet system that floats on gastric fluid for multipulse release of active substance and respective processes of producing same and a cup-shaped envelope of same | |
JP2015500812A (en) | Acamprosate formulation, method of use thereof, and combination containing the same | |
AU2008255254B2 (en) | A pharmaceutical tablet system that floats on gastric fluid for multipulse release of active substance and respective processes of producing same and a cup-shaped envelope of same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002716969 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002247893 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2441123 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 028074319 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002582906 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002716969 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10473055 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002716969 Country of ref document: EP |